In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells

British Journal of Cancer

Volumn 111, Issue 8, 2014, Pages 1562-1571

  Jiang, P ^a   Mukthavaram, R ^a   Chao, Y ^a   Nomura, N ^a   Bharati, I S ^a   Fogal, V ^a   Pastorino, S ^a   Teng, D ^b   Cong, X ^a   Pingle, S C ^a   Kapoor, S ^c   Shetty, K ^c   Aggrawal, A ^c   Vali, S ^c   Abbasi, T ^c   Chien, S ^b   Kesari, S ^a,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CELLWORKS GROUP INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID;

ANIMAL; AUTOPHAGY; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL PROLIFERATION; COMPUTER SIMULATION; DISEASE MODEL; DRUG EFFECTS; HUMAN; IN VITRO STUDY; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IN VITRO TECHNIQUES; MEVALONIC ACID; MICE; MICE, NUDE;

EID: 84908877056     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.431     Document Type: Article

References (43)

1. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J (1980) Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77: 3957-3961.
2. Benn M, Tybjaerg-Hansen A, Stender S, Frikke-Schmidt R, Nordestgaard BG (2011) Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst 103: 508-519.
3. Bergheanu SC, Reijmers T, Zwinderman AH, Bobeldijk I, Ramaker R, Liem AH, van der Greef J, Hankemeier T, Jukema JW (2008) Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr Med Res Opin 24: 2477-2487.
4. Boudreau DM, Yu O, Johnson J (2010) Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 9: 603-621.
5. Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47.
6. Carlberg M, Dricu A, Blegen H, Wang M, Hjertman M, Zickert P, Hoog A, Larsson O (1996) Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutarylcoenzyme a reductase and cell growth. J Biol Chem 271: 17453-17462.
7. Clendening JW, Penn LZ (2012) Targeting tumor cell metabolism with statins. Oncogene 31: 4967-4978.
8. Colditz GA, Sellers TA, Trapido E (2006) Epidemiology-identifying the causes and preventability of cancer? Nat Rev Cancer 6: 75-83.
9. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH, Minden MD, Penn LZ (1999) Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood 93: 1308-1318.
10. Dudakovic A, Tong H, Hohl RJ (2010) Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration. Invest New Drugs 29: 912-920.
11. Dudakovic A, Wiemer AJ, Lamb KM, Vonnahme LA, Dietz SE, Hohl RJ (2008) Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes. J Pharmacol Exp Ther 324: 1028-1036.
12. Edwards PA, Ericsson J (1999) Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu Rev Biochem 68: 157-185.
13. Endo A (2004) The origin of the statins. Atheroscler Suppl 5: 125-130.
14. Endo A, Kuroda M, Tanzawa K (1976) Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 72: 323-326.
15. Eskelinen EL (2005) Maturation of autophagic vacuoles in Mammalian cells. Autophagy 1: 1-10.
16. Fiorenza AM, Branchi A, Sommariva D (2000) Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res 30: 141-145.
17. Furberg CD, Pitt B (2001) Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2: 205-207.
18. Gbelcova H, Lenicek M, Zelenka J, Knejzlik Z, Dvorakova G, Zadinova M, Pouckova P, Kudla M, Balaz P, Ruml T, Vitek L (2008) Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer 122: 1214-1221.
19. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343: 425-430.
20. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS (2009) The AMPK agonist AICAR inhibits the growth of EGFRvIIIexpressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci USA 106: 12932-12937.
21. Hayashi T, Hirshman MF, Kurth EJ, Winder WW, Goodyear LJ (1998) Evidence for 5' AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 47: 1369-1373.
22. Jackson JH, Cochrane CG, Bourne JR, Solski PA, Buss JE, Der CJ (1990) Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci USA 87: 3042-3046.
23. Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z (1991) Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88: 3628-3632.
24. Jiang P, Mukthavaram R, Chao Y, Bharati IS, Fogal V, Pastorino S, Cong X, Nomura N, Gallagher M, Abbasi T, Vali S, Pingle SC, Makale M, Kesari S (2014) Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. J Transl Med 12: 13.
25. Jones KD, Couldwell WT, Hinton DR, Su Y, He S, Anker L, Law RE (1994) Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun 205: 1681-1687.
26. Kajinami K, Mabuchi H, Saito Y (2000) NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin Investig Drugs 9: 2653-2661.
27. Keyomarsi K, Sandoval L, Band V, Pardee AB (1991) Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51: 3602-3609.
28. Leszczynska A, Burzynska B, Plochocka D, Kaminska J, Zimnicka M, Kania M, Kiliszek M, Wysocka-Kapcinska M, Danikiewicz W, Szkopinska A (2009) Investigating the effects of statins on cellular lipid metabolism using a yeast expression system. PLoS One 4: e8499.
29. Levine B (2007) Cell biology: autophagy and cancer. Nature 446: 745-747.
30. Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6: 463-477.
31. Mathew R, Karantza-Wadsworth V, White E (2007) Role of autophagy in cancer. Nat Rev Cancer 7: 961-967.
32. Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367: 1792-1802.
33. Pingle SC, Sultana Z, Pastorino S, Jiang PF, Mukthavaram R, Chao Y, Bharati IS, Nomura N, Makale M, Abbasi T, Kapoor S, Kumar A, Usmani S, Agrawal A, Vali S, Kesari S (2014) In Silico deterministic modeling predicts drug sensitivity of patient-derived cancer cells. J Transl Med 12: 128.
34. Sane KM, Mynderse M, Lalonde DT, Dean IS, Wojtkowiak JW, Fouad F, Borch RF, Reiners Jr JJ, Gibbs RA, Mattingly RR (2010) A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells. J Pharmacol Exp Ther 333: 23-33.
35. Schenk B, Fernandez F, Waechter CJ (2001) The inside and outside of dolichyl phosphate biosynthesis and recycling in the endoplasmic reticulum. Glycobiology 11: 61R-70
36. R. Siddals KW, Marshman E, Westwood M, Gibson JM (2004) Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways. J Biol Chem 279: 38353-38359.
37. Spiro RG (2002) Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 12: 43R-56
38. R. Thurnher M, Nussbaumer O, Gruenbacher G (2012) Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 18: 3524-3531.
39. Tobert JA (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2: 517-526.
40. Tsan YT, Lee CH, Wang JD, Chen PC (2012) Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 30: 623-630.
41. Vakana E, Altman JK, Platanias LC (2011) Targeting AMPK in the treatment of malignancies. J Cell Biochem 113: 404-409.
42. Williams AB, Li L, Nguyen B, Brown P, Levis M, Small D (2012) Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood 120: 3069-3079.
43. Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukaemia 16: 508-519.